FDA indefinitely delays meeting to review first over-the-counter birth control

By Abigail Adcox

Published October 26, 2022 9:28pm ET

FDA indefinitely delays meeting to review first over-the-counter birth control — President Trump signed into law the FDA Reauthorization Act of 2017 on Friday. It reauthorizes a program in which drug and device makers pay the FDA a fee for every new product application, and the agency uses that money to hire more people and speed up approvals. (AP Photo/Andrew Harnik, File) | Andrew Harnik

The Food and Drug Administration has indefinitely postponed a joint meeting between two outside panels to review the first application for over-the-counter birth control.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

FDA indefinitely delays meeting to review first over-the-counter birth control

Recommended Stories

Mifepristone on trial: What to know about the Supreme Court oral arguments

Mifepristone on trial: What to know about the Supreme Court oral arguments

Senate hearing set for Trump FDA pick embraced by anti-abortion movement

Full midterm coverage.Deeper analysis.

Tag: